(Reuters) - Eli Lilly & Co's Elanco Animal Health unit on Thursday said it expects its initial public offering of 62.9 million shares to raise up to $1.45 billion.
The IPO is expected to be priced between $20-$23 per share. At the high end of the range, the company would have a valuation of about $8 billion.
In July, Lilly said it would take Elanco public, marking the end of a nine-month review that weighed options for the unit.
Analysts have cited the strong growth of top animal-health company Zoetis Inc (NYSE:ZTS) since Pfizer (NYSE:PFE) listed it about five years ago.
Zoetis' IPO https://www.reuters.com/article/us-zoetis-idUSBRE90U1EE20130131 raised $2.2 billion and the company currently has a market capitalization of $43 billion.
For the six months ended June 30, Elanco's net income was$9.9 million and the company brought in revenue of $1.5 billion.